DNA Process Development and Manufacturing Summit | Boston, MA | March 5-7, 2024

Memo

With the cell and gene therapy industry surging, rapid advances in mRNA-based therapies, and the advent of DNA vaccines, the demand for quality DNA as a critical starting and therapeutic material has skyrocketed in recent years. The Inaugural DNA Process Development and Manufacturing Summit is the only forum solely dedicated to increasing plasmid and cell-free based DNA production while reducing costs, time, and ensuring regulatory compliance. Meet 80+ DNA production experts over 3 days packed with deep-dive workshops, data-led presentations, and dedicated discussion and networking sessions to address the most pressing challenges of producing DNA, brought together by our 18+ expert speakers from leading companies like Sanofi, Roche, Genentech, Pfizer and more. If you want to gain higher yields of top-quality DNA while reducing costs and time, then this summit is for you!   URLs:Tickets: https://go.evvnt.com/2007685-2?pid=5569Brochure: https://go.evvnt.com/2007685-3?pid=5569 Date and Time: On Tue, 05 Mar 2024 08:00 - Thu, 07 Mar 2024 15:45 Venue details: Hilton Boston Back Bay, 40 Dalton Street, Boston, Massachusetts, 02115, United States Prices:Drug Developer Pricing - Conference + 2 Workshops: USD 4297.00,Drug Developer Pricing - Conference + 1 Workshop: USD 3648.00,Drug Developer Pricing - Conference Only: USD 2999.00,Academic and Not-For-Profit Pricing - Conference + 2 Workshops: USD 3697.00,Academic and Not-For-Profit Pricing - Conference + 1 Workshop: USD 3148.00,Academic and Not-For-Profit Pricing - Conference Only: USD 2599.00,Standard Pricing - Conference + 2 Workshops: USD 5297.00,Standard Pricing - Conference + 1 Workshop: USD 4548.00,Standard Pricing - Conference Only: USD 3799.00 Speakers: Anna Ernst, Associate Director, DNA Process Development, BioNTech, Basak Clements, Global Head of Material Science, Pharma Technology Cell and Gene Therapy, Genentech, Bin Li, Plasmid Production Leader, Sanofi, Carlos Castaneda, Principal Scientist, Pfizer, Cristina Zembrana-Echevarria, Drug Substance Process Development Scientist, Omega Therapeutics, Einar Jonesbu Director, Head of CMC Process and Supply, Nykode Therapeutics, James Osborn, Senior Scientist, Merck and Co, Jennifer Tong Sun, Senior Scientist II, US Pharmacopiea, Jing Liao, Director of Vector Development and Operations, Alexion Pharmaceuticals, Joseph Russo, Senior Principal Scientist, Pfizer, Justin Aldridge, Vice President of Regulatory Affairs CMC, AskBio, Knut Fredrik Seip, Associate Director, Head of Analytical Sciences, Nykode Therapeutics, Lawrence Thompson, Associate Research Fellow, Pfizer, Lili Belcastro, Senior Principal Scientist, Bristol Myers Squibb, Marcel de Vocht, Scientific Director Drug Substance Development, Janssen R AND D, Mehak Gupta, Senior Research Scientist, Vertex Pharmaceuticals , Michael Homsy, Senior Scientist, Merck and Co, Michael Kaempf, Lead Nucleic Acid Sciences, Roche, Nicolas Chaudet, Local Head of mRNA and pDNA Process Development, Sanofi, Steven Hersch, Senior Scientist - Molecular Genetics, Mediphage Bioceuticals